High materiality8/10
Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley
Why it may matterVerify against the original reporting
Upside thesis reinforced by higher target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
TRVI received an analyst target update from Morgan Stanley.
- Morgan Stanley raises TRVI target to $23 (from $20).
Key facts
- 01
Target: $23
- 02
Posted price: $18.23
- 03
Analyst firm: Morgan Stanley
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.